Refine by
Spinal Cord Articles & Analysis
93 news found
CD BioSciences, a US-based biotechnology company focusing on the development of imaging technologies, proudly announces an extensive portfolio of Nervous System Tissue Microarrays designed to support neuroscience research. This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into neurological ...
CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug ...
ByCELLINK
Patent provides protection for High Frequency Spinal Cord Stimulation with Beat Technology Vancouver, Washington – March 20, 2015 – Meagan Medical Inc., a clinical research and medical device development company focused on investigating and developing optimal ways of managing and controlling pain, announced today the issuance of a key patent related to a unique ...
Europe-wide aid project for the protection of people with paraplegia Cologne, 28/05/2020 – COVID-19 can be particularly dangerous for people with severe spinal cord injuries. That is why FARCO-PHARMA supports the European Spinal Cord Injury Federation (ESCIF) and the Association of Paraplegics in Germany e.V. (FGQ) with the supply of free protective masks for the caregivers of this ...
Congratulations to the ONWARD team for the incredible progress they are making in the field of neuroengineering! In recent days, numerous media have reported the news of a great advance for science, and especially for all those people with spinal cord injury and their medical and caregiver teams. The ONWARD team has developed an epidural electrical stimulation system using electrodes placed ...
Helena López; why did you decide to become a physiotherapist? Because I like dealing with people, I like helping, I like healthcare… All these reasons were leading me towards medicine, but, in that case, I would spend little time with the patient. I preferred the contact, to be more involved in their evolution. And what made me decide, specifically for the field of neurology, was ...
After creating 7 iterative versions of the exoskeleton prototype that have been tested in individuals with spinal cord injury to validate product-market fit and receive early feedback in order to adapt, change and redesign the device, we have frozen the design of the ABLE Exoskeleton. The final design will be revealed at RehabWeek, the leading conference in rehabilitation technology, in Rotterdam ...
We interviewed Prof. Dr. Ing. Rüdiger Rupp, a key opinion leader in the field of rehabilitation technology with more than 25 years of clinical experience, to talk about rehabilitation, exoskeleton technology, clinical trials and many more. Prof. Dr. Ing. Rüdiger Rupp is the Head of Experimental Neurorehabilitation at the Heidelberg University Hospital in Germany. Throughout his ...
We performed 2 clinical trials in leading neurorehabilitation hospitals in Germany and Spain proving safety, feasibility and usability of the exoskeleton in a clinical setting, and showing significant improvements in clinical outcomes and benefits in rehabilitation. A Multicentric Clinical investigation in Institut Guttmann (Spain) and Heidelberg University Hospital (Germany), leading European ...
We are pleased to announce that “EngageABLE”, a project of ABLE Human Motion in collaboration with the dutch hospital Sint Maartenskliniek, has been awarded for funding by DIH-HERO. The goal of this project is to enhance the capabilities of the ABLE Exoskeleton to promote users’ motivation and faster learning. DIH-HERO is an independent platform that connects Digital Innovation ...
Eikonoklastes Therapeutics, a preclinical biotech company developing treatments for today’s most challenging diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with ...
The biggest difference between spinal blocks vs epidurals is their amount of pain relief: spinal blocks provide total pain relief, while epidurals provide partial pain relief. The reason for this difference is that the former is an anesthetic, while the latter is an analgesic—no sensation versus no pain. But pain elimination comes with a total lack of feeling in the lower body, due to ...
Roughly 8% of U.S. adults suffer from persistent or chronic back pain. That’s around 65 million people who are prevented from engaging in daily activities. Many are forced to miss days of work due to injury. With rising healthcare costs, many back pain sufferers think that they are left without a real solution, until they try epidural injections. An epidural injection is the infusion of ...
Small procedures on the body, like a skin biopsy, are great candidates for local anesthesia. An injection or topical cream may be used. If you’ve ever had an injection by a dentist, you’ve had a local anesthetic. Fast-acting, virtually pain-free and convenient, local anesthetics enable much of medicine to occur. Patients can remain awake and leave following their procedure. After ...
September is National Spinal Cord Injury (SCI) Awareness Month. With over 17,000 new spinal cord injuries taking place every year in the U.S., there is a significant need to call attention to the severity of spinal cord injuries and for continued research to aid in finding a cure. To sustain an SCI is extremely traumatic for the individual, and it also takes a toll on their family, friends, ...
Every year, the month of August is nationally recognized as Spinal Muscular Atrophy (SMA) Awareness Month. This month-long awareness campaign serves as an important time to demonstrate support and help promote awareness for this rare disease affecting lives across the world. WHAT IS SMA? Affecting 4 people in every 100,000 in the U.S., Spinal Muscular Atrophy (SMA) is a genetic, progressive ...
Nalu Medical, Inc. (“Nalu”), a private company focused on innovative and minimally invasive solutions for chronic neuropathic pain, announced today that the Board of Directors has appointed Thomas “Tom” West as President and Chief Executive Officer. This leadership appointment is effective on August 8th and follows the decision by Earl Fender, Nalu’s current CEO, to ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it has expanded its existing collaboration with Advanced BioMatrix, a division of BICO Group AB (STO: BICO), for Lineage’s HyStem cell/drug delivery technology. Under the expanded collaboration, Advanced ...
AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a shared purpose to free people from a lifetime of genetic disease, today announced preclinical data demonstrating the efficacy and safety of AVR-RD-03 gene therapy in a mouse model of infantile onset Pompe disease. The results, which will be presented today during the “Disease models and Clinical Applications: ...
Ness Ziona, Science Park, May 18, 2022 - Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS and a potential cure for diabetes, is expanding its R&D activity with the exploration of developing a treatment for Multiple Sclerosis (MS). As part of this initiative, the company has signed a service agreement with Hadasit Medical Research Services ...